Evidence map›Paper›PMID 28919634›Full record

ArticleLeukemia2018

Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces the risk of relapse.

P Boddu, J Jorgensen, H Kantarjian, G Borthakur, T Kadia, N Daver, Y Alvarado, N Pemmaraju, P Bose, K Naqvi and 9 more

Abstract readLetter
PubMed Publisher
In one paragraph

Article in Leukemia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022
    Trial
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

P BodduDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
J JorgensenDepartment of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
H KantarjianDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
G BorthakurDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
T KadiaDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
N DaverDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Y AlvaradoDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
N PemmarajuDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
P BoseDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
K NaqviDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
M YilmazDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
S PierceDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
M BrandtDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
C D DiNardoDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
E J JabbourDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
M KonoplevaDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
G Garcia-ManeroDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
J CortesDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
F RavandiDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
University of Texas M.D. Anderson Cancer SPORE-LeukemiaP50CA100632 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KONOPLEVA, MARINA Y · 2003 to 2023
$43.7M
NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA100632
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AgedAged, 80 and overAntineoplastic AgentsFemaleHumansLeukemia, Myeloid, AcuteMaleMethylationMiddle AgedNeoplasm Recurrence, LocalNeoplasm, ResidualPrognosisRecurrenceRiskAntineoplastic Agents

Identifiers

PMID28919634

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.